No Data
HAITONG INT'L: Bullish on the bottom reversal of the Traditional Chinese Medicine Industry, with the State-owned Enterprise Reform and mergers and acquisitions resonating in development.
As aging continues to intensify, the demand in the Silver economy and chronic disease medication-related fields is viewed as Bullish.
beijing tongrentang channel research: the high-end series has started to layout, there are still "gaps" in the out-of-hospital channels, and mergers and acquisitions have taken root in the in-hospital market | company research
① This Friday, the chairman of beijing tongrentang, Di Shubing, officially assumes the role of general manager of beijing tongrentang Group. ② The high-end imperial medicine series is primarily sold in beijing tongrentang pharmacies and remains hard to find in some city chain pharmacies. The company stated that the overall sales situation is in line with expectations. ③ beijing tongrentang Commercial Company acquired 51% of Honghui Medical for 0.105 billion, exploring the medical market, but there are still gaps in the outpatient medium and large chain market.
beijing tongrentang (600085.SH): Shiyi Qingwen Wan has obtained product registration in Canada.
beijing tongrentang (600085.SH) announced that the company's branch institution beijing tongrentang Co., Ltd. tongrentang Pharmaceutical Factory (...)
zhongtai: In Q3 2024, traditional chinese medicine companies are experiencing temporary pressure, while end demand has slightly rebounded.
In the third quarter of 2024, traditional chinese medicine companies are experiencing temporary performance pressure, but gross margin is expected to improve upward from 2025.
Beijing Tongrentang (600085.SH): Currently not carrying out traditional Chinese medicine siasun robot&automation projects.
Gelonghui Nov 8th ǀ Beijing Tongrentang (600085.SH) stated on the interactive platform that the company's main business is the production and sales of Chinese patent medicine, and it is currently not engaged in traditional Chinese medicine siasun robot&automation projects.
Deng Xiaofeng newly invested in a resource stock.
Private equity tycoons Feng Liu and Deng Xiaofeng's latest holdings are here! In the third quarter, Feng Liu's managed Gaoyi Linshan No. 1 Yuanwang Fund entered the top ten list of tradable shareholders of 10 A-share companies, with a total market cap of approximately 19.538 billion yuan. Specifically, in the third quarter, Feng Liu increased his holdings in Beijing Tongrentang, Yantai Dongcheng Biochemicals, and Jonjee Hi-Tech Industrial and Commercial Holding; reduced his holdings in Angel Yeast Co., Ltd. and Nanjing King-Friend Biochemical Pharmaceutical; maintained his position unchanged in Hangzhou Hikvision Digital Technology, LB Group Co., Ltd., Shengyi Technology, Xinxiang Richful Lube Additive, and Shanghai Titan Scientific Co., Ltd. Deng Xiaofeng's managed Gaoyi Xiaofeng No. 2 Fund entered the top ten list of tradable shareholders of 13 A-share companies in the third quarter, with a total market cap of approximately 7.917 billion yuan. Gaoyi Xiaofeng Hongyuan Fund
